This report describes the experience of three patients with refractory autoimmune encephalitis who received a specific sequence of treatments. The patients first received efgartigimod, followed by rituximab. All three individuals showed substantial clinical improvement, and each achieved sustained remission after the second medication was administered. No evidence of disease relapse was observed during the observation period.
The study notes that these findings come from a small case series, meaning the results are based on preliminary observations rather than a large, controlled trial. Because the group was so small, these results cannot prove that this treatment works for everyone or that it is better than other options.
While the patients tolerated the treatment well with no reported safety concerns, doctors should be cautious. This approach may represent a viable therapeutic option for similar difficult-to-treat cases, but it is not yet a standard recommendation. More research is needed to confirm these benefits and ensure safety in a broader population.